Anthony Vaca, MD
Psychiatry · Sioux Falls, SDNPI 1700858248
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,299 of the $15,173 with a category attached, or 81.1%. Otsuka America Pharmaceutical, Inc. accounts for 92.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $12,503 and has fallen 97.4% since, to $322 in 2025. Among psychiatry clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $194.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$14K
- Teva Pharmaceuticals USA, Inc.$426
- Neurocrine Biosciences, Inc.$233
- Alkermes, Inc.$135
- E.r. Squibb & Sons, L.L.C.$120
- Johnson & Johnson$117
- plus $149 from 4 others
What the payments were for
- Speaking & faculty fees$12,29981%
- Travel & lodging$1,4279%
- Food & beverage$1,44710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 29 | $13,994 |
| Teva Pharmaceuticals USA, Inc. | 14 | $426 |
| Neurocrine Biosciences, Inc. | 11 | $233 |
| Alkermes, Inc. | 8 | $135 |
| E.r. Squibb & Sons, L.L.C. | 2 | $120 |
| Johnson & Johnson | 7 | $117 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Novo Nordisk | 1 | $23 |
| AbbVie | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$13,435
- UZEDY$254
How this compares
$15,173 in reported general payments places this provider in the 90th percentile of 79 psychiatry providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 11 | $109 |
| Lorazepam | 13 | $46 |
| Clonazepam | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Sioux Falls
- James ChiuSioux Falls$1.7M
- Hari KannanSioux Falls$913K
- Rajesh SinghSioux Falls$393K
- Mackenzie MertzSioux Falls$4K
- Georgiana NussSioux Falls$4K
- Sandra Peynado RojasSioux Falls$3K
- David ErmerSioux Falls$3K
- Clay PavlisSioux Falls$2K
- William FullerSioux Falls$2K
- Xiaofan LiSioux Falls$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.